Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Publication date: Available online 16 April 2019Source: The Lancet HaematologyAuthor(s): Steven W Pipe, Midori Shima, Michaela Lehle, Amy Shapiro, Sammy Chebon, Katsuyuki Fukutake, Nigel S Key, Agnès Portron, Christophe Schmitt, Maria Podolak-Dawidziak, Nives Selak Bienz, Cedric Hermans, Avrita Campinha-Bacote, Anna Kiialainen, Kathelijne Peerlinck, Gallia G Levy, Victor Jiménez-YusteSummaryBackgroundEmicizumab, a subcutaneously administered, humanised, bispecific, monoclonal antibody, is approved to treat people with haemophilia A of all ages with and without coagulation factor VIII (FVIII) inhibitors. HAVEN...
Source: The Lancet Haematology - April 17, 2019 Category: Hematology Source Type: research

The effect of emicizumab regimen on haemophilia outcomes
Publication date: Available online 16 April 2019Source: The Lancet HaematologyAuthor(s): Margaret V Ragni (Source: The Lancet Haematology)
Source: The Lancet Haematology - April 17, 2019 Category: Hematology Source Type: research

Gene therapy for Wiskott-Aldrich syndrome: here to stay
Publication date: Available online 10 April 2019Source: The Lancet HaematologyAuthor(s): Fabio Candotti (Source: The Lancet Haematology)
Source: The Lancet Haematology - April 11, 2019 Category: Hematology Source Type: research

Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study
Publication date: Available online 10 April 2019Source: The Lancet HaematologyAuthor(s): Francesca Ferrua, Maria Pia Cicalese, Stefania Galimberti, Stefania Giannelli, Francesca Dionisio, Federica Barzaghi, Maddalena Migliavacca, Maria Ester Bernardo, Valeria Calbi, Andrea Angelo Assanelli, Marcella Facchini, Claudia Fossati, Elena Albertazzi, Samantha Scaramuzza, Immacolata Brigida, Serena Scala, Luca Basso-Ricci, Roberta Pajno, Miriam Casiraghi, Daniele CanaruttoSummaryBackgroundWiskott-Aldrich syndrome is a rare, life-threatening, X-linked primary immunodeficiency characterised by microthrombocytopenia, infections, ecze...
Source: The Lancet Haematology - April 11, 2019 Category: Hematology Source Type: research

Monoclonal antibody-drug conjugates in B-cell lymphomas
Publication date: Available online 29 March 2019Source: The Lancet HaematologyAuthor(s): Annalisa Chiappella, Umberto Vitolo (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 31, 2019 Category: Hematology Source Type: research

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Publication date: Available online 29 March 2019Source: The Lancet HaematologyAuthor(s): Franck Morschhauser, Ian W Flinn, Ranjana Advani, Laurie H Sehn, Catherine Diefenbach, Kathryn Kolibaba, Oliver W Press, Gilles Salles, Hervé Tilly, Andy I Chen, Sarit Assouline, Bruce D Cheson, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Surai Jones, Ji Cheng, Dan Lu, Elicia Penuel, Jamie HirataSummaryBackgroundAntibody–drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials. The aim of this multicentre, open-label, phase 2 stud...
Source: The Lancet Haematology - March 31, 2019 Category: Hematology Source Type: research

Sickle-cell anaemia—keeping alive Wethers' legacy
Publication date: April 2019Source: The Lancet Haematology, Volume 6, Issue 4Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

Improvements in haploidentical transplantation for sickle cell disease and β-thalassaemia
Publication date: April 2019Source: The Lancet Haematology, Volume 6, Issue 4Author(s): John Tisdale (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?
Publication date: April 2019Source: The Lancet Haematology, Volume 6, Issue 4Author(s): Theo de Witte (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
This study is registered with ClinicalTrials.gov, number NCT02103478.FindingsBetween Oct 28, 2014, and Nov 13, 2015, we enrolled 44 eligible patients (of 75 screened) with previously treated or newly diagnosed myelodysplastic syndromes or chronic myelomonocytic leukaemia; 43 of the enrolled patients were evaluable. Participants were treated in five cohorts: cohorts 1–4 included six evaluable patients each; cohort 5 included 19 patients in a 13-patient expansion. Dose-dependent increases in decitabine AUC and peak plasma concentration occurred with each cohort dose escalation. There was no evident increase in toxicity...
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

10-day vs 5-day decitabine: equivalence cannot be concluded – Authors' reply
Publication date: April 2019Source: The Lancet Haematology, Volume 6, Issue 4Author(s): Nicholas J Short, Farhad Ravandi (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

Can apixaban prevent venous thromboembolism better than rivaroxaban?
Publication date: April 2019Source: The Lancet Haematology, Volume 6, Issue 4Author(s): Craig I Coleman, William L Baker (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

Can apixaban prevent venous thromboembolism better than rivaroxaban?
Publication date: April 2019Source: The Lancet Haematology, Volume 6, Issue 4Author(s): Mikhail Akbashev, Bhavin Adhyaru, Arthur Allen (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

Can apixaban prevent venous thromboembolism better than rivaroxaban? – Authors' reply
Publication date: April 2019Source: The Lancet Haematology, Volume 6, Issue 4Author(s): Ghadeer K Dawwas, Joshua Brown, Eric Dietrich, Haesuk Park (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

10-day vs 5-day decitabine: equivalence cannot be concluded
Publication date: April 2019Source: The Lancet Haematology, Volume 6, Issue 4Author(s): Gerwin Huls, Stefan Suciu, Pierre Wijermans, Michal Kicinski, Michael Lübbert (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2019 Category: Hematology Source Type: research

Improving the conditioning regimen in multiple myeloma
Publication date: Available online 22 March 2019Source: The Lancet HaematologyAuthor(s): María-Victoria Mateos, Verónica González-Calle (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 23, 2019 Category: Hematology Source Type: research

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
This study was funded in part by the National Institutes of Health (NIH) through MD Anderson's Cancer Center Support Grant ( CA016672). (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 23, 2019 Category: Hematology Source Type: research

Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial
This study was done at Johns Hopkins Hospital (Baltimore, MD, USA). Patients aged 2–70 years receiving their first bone marrow transplant were eligible for inclusion in the study. Patients received rabbit-derived intravenous anti-thymocyte globulin 0·5 mg/kg on day −9 and 2 mg/kg on days −8 and −7, intravenous fludarabine 30 mg/m2 on days −6 to −2, intravenous cyclophosphamide 14·5 mg/kg on days −6 and −5, and total body irradiation 400 cGy administered as a single fraction on day −1. We collected unmanipulated bone marrow and infused on day 0. GVHD prophy...
Source: The Lancet Haematology - March 14, 2019 Category: Hematology Source Type: research

Improvments in haploidentical transplantation for sickle cell disease and β-thalassaemia
Publication date: Available online 14 March 2019Source: The Lancet HaematologyAuthor(s): John Tisdale (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 14, 2019 Category: Hematology Source Type: research

Myeloma cast nephropathy: the dusk of high cutoff haemodialysis
Publication date: Available online 11 March 2019Source: The Lancet HaematologyAuthor(s): Marion Sallée, Stéphane Burtey (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 12, 2019 Category: Hematology Source Type: research

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial
Publication date: Available online 11 March 2019Source: The Lancet HaematologyAuthor(s): Colin A Hutchison, Paul Cockwell, Veronica Moroz, Arthur R Bradwell, Lesley Fifer, Julian D Gillmore, Mark D Jesky, Markus Storr, Julie Wessels, Christopher G Winearls, Katja Weisel, Nils Heyne, Mark CookSummaryBackgroundIn multiple myeloma, severe acute kidney injury due to myeloma cast nephropathy is caused by pathogenic free light chain immunoglobulin in serum. High cutoff haemodialysis (HCO-HD) can remove large quantities of free light chain immunoglobulin from serum, but its effect on clinical outcomes is uncertain. We therefore a...
Source: The Lancet Haematology - March 12, 2019 Category: Hematology Source Type: research

Excellent outcomes for patients with B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses
Publication date: Available online 27 February 2019Source: The Lancet HaematologyAuthor(s): David T Teachey (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
Publication date: Available online 27 February 2019Source: The Lancet HaematologyAuthor(s): Catriona Parker, Shekhar Krishnan, Lina Hamadeh, Julie A E Irving, Roland P Kuiper, Tamas Révész, Peter Hoogerbrugge, Jeremy Hancock, Rosemary Sutton, Anthony V Moorman, Vaskar SahaSummaryBackgroundThe ALLR3 trial investigated outcomes of children with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. We analysed long-term follow-up outcomes of these patients.MethodsALLR3 was an open-label randomised clinical trial that recruited children aged 1–18 years with B-cell precursor acute...
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

A new standard treatment for prevention of GvHD after HCT?
Publication date: March 2019Source: The Lancet Haematology, Volume 6, Issue 3Author(s): Sung Won Choi (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care
Publication date: March 2019Source: The Lancet Haematology, Volume 6, Issue 3Author(s): Joshua ML Casan, Alison Barraclough, Jake Shortt, Eliza A Hawkes (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care – Authors' reply
Publication date: March 2019Source: The Lancet Haematology, Volume 6, Issue 3Author(s): Wyndham H Wilson (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

Correction to Lancet Haematol 2018; 5: e563–98
Publication date: March 2019Source: The Lancet Haematology, Volume 6, Issue 3Author(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

Correction to Lancet Haematol 2019; 6: e89–99
Publication date: March 2019Source: The Lancet Haematology, Volume 6, Issue 3Author(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Publication date: March 2019Source: The Lancet Haematology, Volume 6, Issue 3Author(s): Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, Mingwei Fei, Sunil Abhyankar, Zaid Al-Kadhimi, Amin M Alousi, Joseph H Antin, Sally Arai, Kate Bickett, Yi-Bin Chen, Lloyd E Damon, Yvonne A Efebera, Nancy L Geller, Sergio A Giralt, Parameswaran Hari, Shernan G Holtan, Mary M Horowitz, David A Jacobsohn, Richard J JonesSummaryBackgroundPrevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maravi...
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

Health and Brexit: what lies ahead?
Publication date: March 2019Source: The Lancet Haematology, Volume 6, Issue 3Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 28, 2019 Category: Hematology Source Type: research

GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
We report unpublished data on quality of life (QoL) from the original study and the results of a follow-up extension.MethodsIn the original open-label study, patients with acute myeloid and lymphoblastic leukaemia in first or subsequent remission, having sibling HLA-identical allogeneic peripheral blood stem-cell transplantation, were randomly assigned (1:1) to receive ATLG plus standard GVHD prophylaxis with ciclosporin and short-term methotrexate (ATLG group) or standard GVHD prophylaxis without ATLG (non-ATLG group). Conditioning regimens were cyclophosphamide 120 mg/kg with either total body irradiation (12 Gy) or busu...
Source: The Lancet Haematology - February 26, 2019 Category: Hematology Source Type: research

Paediatric pulmonary embolism: a pathway to improved outcomes
Publication date: Available online 13 February 2019Source: The Lancet HaematologyAuthor(s): Vera Ignjatovic (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 14, 2019 Category: Hematology Source Type: research

Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study
Publication date: Available online 13 February 2019Source: The Lancet HaematologyAuthor(s): Marie-Claude Pelland-Marcotte, Catherine Tucker, Alicia Klaassen, Maria Laura Avila, Ali Amid, Nour Amiri, Suzan Williams, Jacqueline Halton, Leonardo R BrandãoSummaryBackgroundLittle is known about severe pulmonary embolism in children. We aimed to report pulmonary embolism outcomes, identify risk factors for unfavourable outcomes, and evaluate the discriminative ability of two clinical-severity indices in children.MethodsIn this retrospective cohort study, we included consecutive patients aged 18 years or younger with acute...
Source: The Lancet Haematology - February 14, 2019 Category: Hematology Source Type: research

Frailty in multiple myeloma: the need for harmony to prevent doing harm
Publication date: Available online 6 February 2019Source: The Lancet HaematologyAuthor(s): Sonja Zweegman, Alessandra Larocca (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 7, 2019 Category: Hematology Source Type: research

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
Publication date: Available online 6 February 2019Source: The Lancet HaematologyAuthor(s): Gordon Cook, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Vallari Shah, Martin F Kaiser, Sarah R Brown, Walter M Gregory, J Anthony Child, Faith E Davies, Gareth J Morgan, David A Cairns, Graham H JacksonSummaryBackgroundTolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict overall survival in patients with multiple myeloma who were ineligible for stem-cell transplantatio...
Source: The Lancet Haematology - February 7, 2019 Category: Hematology Source Type: research

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
We report unpublished data on quality of life (QoL) from the original study and the results of a follow-up extension.MethodsIn the original open-label study, patients with acute myeloid and lymphoblastic leukaemia in first or subsequent remission, having sibling HLA-identical allogeneic peripheral blood stem-cell transplantation, were randomly assigned (1:1) to receive ATLG plus standard GVHD prophylaxis with ciclosporin and short-term methotrexate (ATLG group) or standard GVHD prophylaxis without ATLG (non-ATLG group). Conditioning regimens were cyclophosphamide 120 mg/kg with either total body irradiation (12 Gy) or busu...
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

To treat, or not to treat: the dilemma for pregnant women
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Is venous thromboembolism a problem in patients with cancer in palliative care?
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Per Morten Sandset, Anders E A Dahm (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

In-vivo T-cell depletion: burden of morbidity versus survival
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Mary Eapen (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Stefano Molica, Emili Montserrat (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Clare White, Simon I R Noble, Max Watson, Flavia Swan, Victoria L Allgar, Eoin Napier, Annmarie Nelson, Jayne McAuley, Jennifer Doherty, Bernadette Lee, Miriam J JohnsonSummaryBackgroundThe prevalence of deep venous thrombosis in patients with advanced cancer is unconfirmed and it is unknown whether current international thromboprophylaxis guidance is applicable to this population. We aimed to determine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist palliative care units (SPCUs).MethodsWe...
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, Marshall T Schreeder, Tanya Siddiqi, Christopher R Flowers, Jonathon B Cohen, Jan A Burger, William G Wierda, Susan O'Brien, Peter Sportelli, Hari P Miskin, Michelle A Purdom, Michael S Weiss, Nathan H FowlerSummaryBackgroundTherapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies.Methods...
Source: The Lancet Haematology - January 31, 2019 Category: Hematology Source Type: research

Eltrombopag use in higher risk myeloid cancers: fitting a square “pag” into a round hole?
Publication date: Available online 29 January 2019Source: The Lancet HaematologyAuthor(s): Rena Buckstein (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 29, 2019 Category: Hematology Source Type: research

Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study
This study investigated safety and efficacy of eltrombopag versus placebo during anthracycline-based induction treatment of patients with acute myeloid leukaemia.MethodsIn this randomised, double-blind, phase 2 study, treatment-naive patients were recruited from clinical centres across 10 countries (Australia, Belgium, Canada, Greece, Hungary, Israel, South Korea, Poland, Russia, and the USA). Patients with acute myeloid leukaemia of any subtype except M3 and M7 were stratified by antecedent malignant haematological disorder (yes or no) and age (18–60 years or>60 years) and were then randomly assigned (1:1) using ...
Source: The Lancet Haematology - January 29, 2019 Category: Hematology Source Type: research

BTK/PD-1 blockade for treatment of Richter's transformation
Publication date: Available online 11 January 2019Source: The Lancet HaematologyAuthor(s): Pek Sang Tang, Constantine S Tam (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 12, 2019 Category: Hematology Source Type: research

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Publication date: Available online 11 January 2019Source: The Lancet HaematologyAuthor(s): Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch, Maria Dolores Caballero Barrigón, Andrzej Hellmann, Bryone Kuss, David D F Ma, Fatih Demirkan, Münci Yağci, Netanel A Horowitz, Paula Marlton, Raul Cordoba, Tomasz WrobelSummaryBackgroundPreclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrut...
Source: The Lancet Haematology - January 12, 2019 Category: Hematology Source Type: research

Closing in on targeted therapy for acute myeloid leukaemia
Publication date: January 2019Source: The Lancet Haematology, Volume 6, Issue 1Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 5, 2019 Category: Hematology Source Type: research

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma
Publication date: January 2019Source: The Lancet Haematology, Volume 6, Issue 1Author(s): Stephen M Ansell (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 5, 2019 Category: Hematology Source Type: research

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
This study is registered with ClinicalTrials.gov, number NCT03114683, and is ongoing.FindingsBetween April 19, 2017, and Nov 1, 2017, 96 patients were enrolled and commenced treatment. Four patients, whose diagnosis was not subsequently confirmed by the central pathology laboratory, were excluded from the full analysis set. Ten patients discontinued treatment. Median duration of follow-up was 10·5 months. In the full analysis set (n=92), 74 patients (80·4%; 95% CI 70·9–88·0) had an IRRC-assessed objective response before the analysis cutoff date of April 16, 2018. 89 (93%) of 96 patients h...
Source: The Lancet Haematology - January 5, 2019 Category: Hematology Source Type: research

The best direct-acting oral anticoagulant for treatment of venous thromboembolism?
Publication date: Available online 14 December 2018Source: The Lancet HaematologyAuthor(s): Corinne Frere, Dominique Farge (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 15, 2018 Category: Hematology Source Type: research